Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based Director operating in the Health Diagnostics space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Eric Boutin
Managing Director of dRx Capital
Eric Boutin was Founder | CEO of Evolve, acquired by HubSpot (NYSE: HUBS). He was Founder | CEO of Good Start Genetics, acquired by Invitae (NYSE: NVTA). He was Founder | VP of Flex Pharma, IPO (NASDAQ: FLKS). Eric was an EIR at Longwood Fund, and Founder of HBS Angels Boston. He holds a BA from Duke University, and an MBA from Harvard.
Follow Eric Boutin:
About dRx Capital: Novartis Digital Health Venture Capital
Shankar Balasubramian
Co-Founder and Director of Cambridge Epigenetix
Sir Shankar is Founder of two companies and the principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN. Sir Shankar’s technology has made routine, accurate, low-cost sequencing of human genomes a reality, has revolutionised biology and accelerated the development of genomic personalised medicine. Sir Shankar is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and Senior Group Leader at the Cancer Research UK Cambridge Institute. His awards include the Royal Medal (2018), the RoyalSociety Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of the Royal Society, the Academy of Medical Sciences and a member of EMBO.
Follow Shankar Balasubramian:
About Ahren Innovation Capital, Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Martin Murphy
Associate Director of Cambridge Epigenetix
Follow Martin Murphy:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Anya Roy
Managing Director of Syrona Health
Anya Roy is the co-founder of Syrona Health.
Follow Anya Roy:
About Syrona Health: Syrona Health is a personalised digital health platform for Chronic Gynaecological/Uterine Conditions like Endometriosis, PCOS etc.
Irina Soltamova Solovyev
Director of Cambridge Oncometrix
Follow Irina Soltamova Solovyev:
About Cambridge Oncometrix: Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer.
Maxim Rossmann
Managing Director of Cambridge Oncometrix
Follow Maxim Rossmann:
About Cambridge Oncometrix, University of Cambridge: Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer.
Catherine Beech
Board of Directors of Exonate
Follow Catherine Beech:
About : Exonate is a biotech company spun out of the University of Nottingham that is focused on alternative splicing of (VEGF) in ophthalmology.
Paul Bailey
Non-Executive Director of Bailey Fisher Executive Search
Paul co-founded Bailey Fisher Executive Search in 1998 and led the growth of the business as Managing Director for 20 years during which time he built the board and management teams for some of the most innovative companies to have emerged from the European technology market. After a successful exit in July 2018, he took on the role of Executive Chairman. Paul was named in the 2016 Maserati 100 and was recognised as one of the most influential business people in Cambridge in 2017. He has held advisory roles with NESTA Impact Investments and New Wave Ventures. Paul joined Martlet Capital in 2019. He is also currently Entrepreneur in Residence at Cambridge Enterprise.
Follow Paul Bailey:
About : Bailey Fisher is an independent executive search firm finding & attracting individuals who have a fundamental impact on business growth.
